Amy Quigley, APRN
Nurse Practitioner · Reno, NVNPI 1225600687
Payments from drug & device makers
Across 109 payments — averaging $28.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$429
- Dexcom, Inc.$379
- Medtronic$371
- Amgen$339
- Mannkind Corporation$237
- Insulet Corporation$212
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,096100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $429 |
| Dexcom, Inc. | 7 | $379 |
| Medtronic | 10 | $371 |
| Amgen(2 entities) | 12 | $339 |
| Mannkind Corporation | 10 | $237 |
| Insulet Corporation | 5 | $212 |
| Novo Nordisk | 5 | $150 |
| Lilly USA, LLC | 5 | $147 |
| GSK | 6 | $118 |
| Tandem Diabetes Care, Inc. | 1 | $117 |
| Abbott | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $57 |
| Aurinia Pharma U.S., Inc. | 2 | $49 |
| Bayer | 2 | $47 |
| Travere Therapeutics, Inc. | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Mylan Specialty L.p. | 2 | $37 |
| Corcept Therapeutics | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $23 |
| Calliditas Therapeutics US Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$150
- Omnipod$130
- DEXCOM G7 GSS (161)$125
- t:slim X2 Insulin Pump with Control-IQ$117
- TEPEZZA$114
- Saxenda$111
- MOUNJARO$108
How this compares
$3,096 in reported general payments places this provider in the 85th percentile of 933 nurse practitioner providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $75,073 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $46,268 |
| TrulicityDulaglutide | 38 | $37,840 |
| JardianceEmpagliflozin | 29 | $34,241 |
| FarxigaDapagliflozin Propanediol | 27 | $31,746 |
| MounjaroTirzepatide | 14 | $19,853 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,734 |
| Levothyroxine Sodium | 58 | $567 |
| Methimazole | 17 | $232 |
| Atorvastatin Calcium | 15 | $90 |
| Metformin Hcl | 12 | $67 |
| Lisinopril | 12 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $150 | $75,07363 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $147 | $57,69352 claims |
| Boehringer IngelheimJardiance | $24 | $34,24129 claims |
| AstraZenecaFarxiga | $429 | $31,74627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 933 nurse practitioner providers in Nevada.
Other nurse practitioner in Reno
- Melissa DelamoraReno$20K
- Darian ThorpReno$18K
- Mary Beth MedinaReno$11K
- Kristen BowmanReno$10K
- Laura HayReno$8K
- Laura HarshReno$7K
- Mary HelmreichReno$7K
- Rhonda StrunkReno$7K
- Rachael HueftleReno$7K
- Rhonda NavarroReno$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.